RESEARCH INTEREST
The Group’s current research activities, as well as those planned for the coming years, focus on:
1) Immune-mediated inflammatory diseases (IMIDs), particularly psoriasis, atopic dermatitis, and hidradenitis suppurativa. The main lines of research are:
a) Immunoregulatory molecules as biomarkers for predicting response to biologic therapies and the severity of IMIDs. This is a group of diseases in which inflammation constitutes the primary pathogenic mechanism. Their long-term impact has been mitigated thanks to the implementation of biologic therapy. However, despite growing knowledge about the etiopathogenesis of these diseases and marked improvements in their management, there is still a lack of markers that can predict disease severity or identify patients who will be refractory to treatment. We are searching for new biomarkers predictive of IMID severity and response to biologics.
b) Gene expression profiles in patients with IMID.
c) Epigenetic biomarkers as predictors of therapeutic response to biologics in psoriasis.
d) Immunoregulatory molecules and their therapeutic potential. We are investigating the role of GCLC in keratinocytes in in vitro models of inflammatory skin diseases.
e) Survival analysis of conventional systemic therapies and biologics in psoriasis.
f) Identification of single nucleotide polymorphisms associated to treatment response in atopic dermatitis and psoriasis.
g) Strategies for optimizing treatment (dose reduction, increasing the dosing interval) in the management of moderate-to-severe psoriasis with systemic agents.
h) Circulating memory T cells in psoriasis, atopic dermatitis and hidradenitis suppurative and their association with treatment response.
i) Comprehensive study of systemic inflammation in chronic inflammatory skin diseases and its association with cardiovascular disease.
j) Association of immunosenescence markers with comorbidities in psoriasis and hidradenitis suppurative.
2) Eczematous dermatitis. Study of the prevalence of allergens responsible for allergic contact dermatitis in the Spanish population.
3) Connective tissue diseases. Determination of the association of myositis-specific autoantibodies and myositis-associated autoantibodies with clinically amyopathic dermatomyositis.
4) Photobiology. Studies on the epidemiology, clinical phenotypes, and photobiology of solar urticaria.
Immunoregulatory molecules as biomarkers predicting response to biological therapies and disease severity in immunemediated inflamatory disorders. BIOMID PROJECT. PIE13/00041. Proyecto coordinado. ISCIII. 2014-2016.
INNPACTO. Estudio de biomarcadores en psoriasis. 2013-2015.
Identificación de microRNAs como biomarcadores de gravedad y respuesta al tratamiento en pacientes con Psoriasis. PI14/01751. ISCIII. 2015-2017.
Esta ayuda está financiada por el Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 y el ISCIII – Subdirección General de Evaluación y Fomento de la Investigación – y cofinanciadas por el Fondo Europeo de Desarrollo Regional, Programa Operativo Crecimiento Inteligente 2014-2020 de acuerdo al Reglamento (UE) Nº 1303/2013.
Regulación de la expresión de CXCL12 y RAPTOR por miRNAs noveles y su papel en el proceso inflamatorio de la Psoriasis. PI17/01972. ISCIII. 2018-2020.
Determinar la importancia de los miRNAs en la inflamación característica de la psoriasis.
Esta ayuda está financiada por el Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 y el ISCIII – Subdirección General de Evaluación y Fomento de la Investigación – y cofinanciadas por el Fondo Europeo de Desarrollo Regional, Programa Operativo Crecimiento Inteligente 2014-2020 de acuerdo al Reglamento (UE) Nº 1303/2013.
Naredo, Esperanza, Moeller, Ingrid, de Miguel, Eugenio, Batlle-Gualda, Enrique, Acebes, Carlos, Brito, Elia, Mayordomo, Lucia, Moragues, Carmen, Uson, Jacqueline, de Agustin, Juan J., Martinez, Agustin, Rejon, Eduardo, Rodriguez, Ana, Dauden, Esteban, Spanish Soc Rheumatology & Spanish, Ultrasound Sch. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology (Oxford) 2011. 50: 1838-1848. FI: 4,058(Q2). PMID: 21700682. DOI: 10.1093/rheumatology/ker078.
de la Fuente H, Perez-Gala S, Bonay P, Cruz-Adalia A, Cibrian D, Sanchez-Cuellar S, Dauden E, Fresno M, García-Diez A, Sanchez-Madrid F. Psoriasis in humans is associated with down-regulation of galectins in dendritic cells. J Pathol 2012. 228: 193-203. FI: 7,585(Q1). PMID: 22271227. DOI: 10.1002/path.3996.
Julià A, Tortosa R, Hernanz JM, Cañete JD, Fonseca E, Ferrándiz C, Unamuno P, Puig L, Fernández-Sueiro JL, Sanmartí R, Rodríguez J, Gratacós J, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno-Ramírez D, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Vanaclocha F, Herrera E, Muñoz-Fernández S, González C, Roig D, Erra A, Acosta I, Fernández-Nebro A, Zarco P, Alonso A, López-Lasanta M, García-Montero A, Gelpí JL, Absher D, Marsal S. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum. Mol. Genet. 2012. 21: 4549-4557. FI: 7,692(Q1). PMID: 22271227. DOI: 10.1002/path.3996.
Gallo E, Cabaleiro T, Román M, Solano-López G, Abad-Santos F, García-Díez A, Daudén E. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol 2013. 169: 819-829. FI: 4,100(Q1). PMID: 23662788. DOI: 10.1111/bjd.12425.
Guinea-Viniegra J, Jiménez M, Schonthaler HB, Navarro R, Delgado Y, Concha-Garzón MJ, Tschachler E, Obad S, Daudén E, Wagner EF. Targeting miR-21 to Treat Psoriasis. Sci. Transl. Med. 2014. . FI: 15,843(Q1). PMID: 24574341. DOI: 10.1126/scitranslmed.3008089.
